[go: up one dir, main page]

MY203254A - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
MY203254A
MY203254A MYPI2020004773A MYPI2020004773A MY203254A MY 203254 A MY203254 A MY 203254A MY PI2020004773 A MYPI2020004773 A MY PI2020004773A MY PI2020004773 A MYPI2020004773 A MY PI2020004773A MY 203254 A MY203254 A MY 203254A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical preparation
rosuvastatin
amlodipine
relates
present
Prior art date
Application number
MYPI2020004773A
Other languages
English (en)
Inventor
Sang Yeop Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67055715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY203254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MY203254A publication Critical patent/MY203254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2020004773A 2018-04-30 2019-04-29 Pharmaceutical preparation MY203254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180050277A KR101992400B1 (ko) 2018-04-30 2018-04-30 약학적 제제
PCT/KR2019/005151 WO2019212214A1 (ko) 2018-04-30 2019-04-29 약학적 제제

Publications (1)

Publication Number Publication Date
MY203254A true MY203254A (en) 2024-06-20

Family

ID=67055715

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004773A MY203254A (en) 2018-04-30 2019-04-29 Pharmaceutical preparation

Country Status (10)

Country Link
KR (1) KR101992400B1 (zh)
CN (1) CN112040933A (zh)
MX (1) MX2020010259A (zh)
MY (1) MY203254A (zh)
PH (1) PH12020551547A1 (zh)
RU (1) RU2756452C1 (zh)
SG (1) SG11202009187YA (zh)
TW (1) TWI697339B (zh)
WO (1) WO2019212214A1 (zh)
ZA (1) ZA202006346B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022260439A1 (ko) * 2021-06-09 2022-12-15 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336922A (zh) * 2008-08-08 2009-01-07 青岛黄海制药有限责任公司 一种瑞舒伐他汀氨氯地平组合物
BR112012011726A2 (pt) * 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물
SG11201405198YA (en) * 2012-03-30 2014-09-26 Dae Woong Pharma Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN103156842B (zh) * 2013-03-08 2014-05-28 南开大学 牛蒡子苷元在制备抗心律失常药物中的用途
EP2974719B1 (en) * 2013-03-14 2019-08-28 Boryung Pharmaceutical Co., Ltd. Pharmaceutical combination drug
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
ES2882672T3 (es) * 2015-07-08 2021-12-02 Hk Inno N Corp Composición farmacéutica que contiene amlodipino, valsartán, y rosuvastatina
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염

Also Published As

Publication number Publication date
SG11202009187YA (en) 2020-10-29
RU2756452C1 (ru) 2021-09-30
TW201946916A (zh) 2019-12-16
CN112040933A (zh) 2020-12-04
MX2020010259A (es) 2020-10-22
PH12020551547A1 (en) 2021-06-07
KR101992400B1 (ko) 2019-06-24
WO2019212214A1 (ko) 2019-11-07
TWI697339B (zh) 2020-07-01
ZA202006346B (en) 2022-01-26

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2017016802A (es) Formulaciones farmaceuticas.
SG11201912161SA (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
MX2016014581A (es) Composiciones de compuestos que modulan nmdar.
MX2021010022A (es) Composicion farmaceutica.
PH12016501841A1 (en) Immunosuppressant formulation
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
IL275935B2 (en) Thiophene-triazole-piperidine-6,2-dione compound, a medicament containing the compound, a pharmaceutical preparation and the compound for use.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
WO2019203755A3 (en) A solid oral dosage form comprising linagliptin
MY203254A (en) Pharmaceutical preparation
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
IN2013MU03370A (zh)
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EP4631500A3 (en) STABLE MULTIPARTICULAR PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN
TR201713954A2 (tr) Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
TR201619184A2 (tr) Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
IN2014MU00043A (zh)